[EN] NEW 5-ALKYNYL-PYRIDINES<br/>[FR] NOUVELLES 5-ALKYNYL-PYRIDINES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2012101186A1
公开(公告)日:2012-08-02
This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of P13Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.
[EN] PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR 2 ACTIVÉ PAR DES PROTÉASES (PAR2)
申请人:PROXIMAGEN LTD
公开号:WO2012101453A1
公开(公告)日:2012-08-02
A compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate thereof (I) Wherein Y, Z, R3, U, R4, m and n are as defined in the claims.
5-alkynyl-pyridine of general formula (I)
their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer.
The groups R
1
to R
6
and n have the meanings given in the claims and in the specification.